台股 » 個股 » 生華科 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

生華科

(6492)
可現股當沖
  • 股價
    41.75
  • 漲跌
    ▲0.10
  • 漲幅
    +0.24%
  • 成交量
    125
  • 產業
    上櫃 生技醫療類股
  • 147人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
生華科 (6492)籌碼相關-富邦-頭份 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

富邦-頭份 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2024/04/23240.7000.0041.0021861.07%
2024/04/18042.0000.0041.9001820.00%
2024/04/09143.9500.0043.5511910.52%
2024/03/26044.2000.0043.0502020.00%
2024/03/25244.6000.0044.5022010.99%
2024/03/20242.1000.0041.5521981.01%
2024/03/12243.5500.0043.6022140.93%
2024/02/1600.00146.8046.75-1426-0.23%
2024/01/1000.00547.7048.05-51,328-0.38%
2023/12/26553.00552.0051.8001,3030.00%
2023/12/15353.6000.0053.5031,2770.23%
2023/12/14253.5000.0053.4021,2740.16%
2023/12/1200.001553.4053.40-151,269-1.18%
2023/12/1100.00554.3054.10-51,266-0.39%
2023/12/0800.00554.0053.80-51,261-0.40%
2023/12/0600.001955.0254.60-191,250-1.52%
2023/12/051956.63357.3055.80161,2371.29%
2023/12/041859.1800.0060.70181,1971.50%
2023/11/271055.50157.5055.2091,1190.80%
2023/11/24156.40155.1054.3001,0970.00%
2023/11/15154.4000.0054.0011,0420.10%
2023/11/14154.4000.0054.8011,0330.10%
2023/11/10154.40356.4354.10-21,010-0.20%
2023/11/09156.401453.1653.40-13948-1.37%
2023/11/08257.3500.0055.4029290.22%
2023/11/07258.90258.2057.8009040.00%
2023/11/0600.00257.8057.40-2861-0.23%
2023/11/03561.24359.6059.4028120.25%
2023/11/02258.001758.4659.10-15744-2.01%
2023/11/012760.971060.3060.40176902.46%
2023/10/31558.101658.6858.80-11506-2.17%
2023/10/30159.801.159.5454.50-0.1369-0.02%
2023/10/27149.4500.0054.4012400.42%
2023/10/261.149.380.147.5049.5011830.55%
2023/10/230.146.9000.0046.450.11490.04%
2023/09/01546.3000.0046.3051533.25%
2023/08/3100.00046.0047.6501510.00%
2023/08/29043.5500.0044.3001390.01%
2023/08/2500.00141.3541.60-1119-0.84%
2023/08/11142.4000.0042.4011280.78%
2023/07/20046.1000.0045.6001300.00%
2023/07/0500.00149.6049.40-1126-0.79%
2023/05/1900.00149.2049.45-1150-0.66%
2023/04/18055.6000.0054.5001800.00%
上櫃「肥貓」董監現形 台嘉碩、大宇資、穩懋、生華科為前四肥Anue鉅亨-18天前
生華科治療新冠、流感等泛病毒感染新藥 將啟動二期臨床Anue鉅亨-2023/11/21
生華科泛病毒感染肺炎新藥 向美申請二期臨床Anue鉅亨-2023/10/19
生華科 相關文章
生華科 相關影音